Andrée Rorive

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale et al. · The Lancet Oncology · 2018 · 533 citations

Surgical Oncology, Breast Oncology, Medicine +7

Codon-specific translation reprogramming promotes resistance to targeted therapy

Francesca Rapino, Sylvain Delaunay, Florian Rambow et al. · Nature · 2018 · 255 citations

Engineering, Novel Therapy, Clinical Translation +5

18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers

Nadia Withofs, Benjamin Grayet, Tino Tancredi et al. · Nuclear Medicine Communications · 2010 · 92 citations · Full text

Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).

Dirk Schadendorf, Paolo A. Ascierto, John B.A.G. Haanen et al. · Journal of Clinical Oncology · 2017 · 25 citations

Neuro-oncology, Oncology, Melanoma +15

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.

Lore Decoster, Isabelle Vande Broek, Bart Neyns et al. · PubMed · 2015 · 24 citations